Meeting Information - The company will hold its second extraordinary general meeting of shareholders in 2025 on July 7, 2025, at 14:00 [1] - Shareholders can participate either in person or via online voting through the Shenzhen Stock Exchange system on the same day [1][2] - The voting options include attending the meeting in person or appointing a proxy to vote on their behalf [2] Voting Procedures - Shareholders can only choose one voting method: either in-person or online voting, with the first valid vote being counted in case of duplicate votes [2] - The meeting will include a proposal to adjust the conversion price of the "Blue Sail Convertible Bond," which requires a two-thirds majority from attending shareholders to pass [3] Registration and Participation - Individual shareholders must present valid identification and proof of share ownership to register for the meeting [4] - Corporate shareholders must be represented by their legal representatives or authorized agents, who must also provide necessary documentation [4] Online Voting Process - Detailed procedures for online voting are provided, allowing shareholders to express their voting opinions on various proposals [5] - The online voting system can be accessed through the specified URL, and shareholders must complete identity verification to participate [5] Contact Information - For inquiries, shareholders can contact the company representatives via provided phone numbers and email [5]

Core Viewpoint - The company proposes to lower the conversion price of its convertible bonds, "蓝帆转债," due to the stock price falling below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [1][4]. Group 1: Convertible Bond Issuance and Adjustment - The total amount of the convertible bonds issued by the company is 314.404 million yuan, approved by the China Securities Regulatory Commission [1]. - The initial conversion price of "蓝帆转债" was set at 17.79 yuan per share, which was later adjusted to 18.64 yuan per share after the company repurchased and canceled 48,148,336 shares [2]. - The board of directors has decided to lower the conversion price to 12.50 yuan per share, effective from May 21, 2024 [3]. Group 2: Conditions for Price Adjustment - The adjustment of the conversion price is triggered when the company's stock price falls below 85% of the current conversion price for at least 15 trading days within a 30-day period [3][4]. - The adjusted conversion price must not be lower than the higher of the average stock price over the 20 trading days prior to the shareholders' meeting and the previous trading day's average price, as well as not lower than the latest audited net asset value per share and the par value of the stock [5]. Group 3: Shareholder Approval and Process - The proposal to adjust the conversion price requires approval from more than two-thirds of the voting rights held by shareholders present at the meeting, excluding those holding the convertible bonds [3][4]. - The company will publish the resolution of the shareholders' meeting, including the adjustment range, registration date, and any suspension of conversion [4].

证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-052 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）第六届董事会第二十 四次会议审议通过，公司决定于2025年7月7日召开2025年第二次临时股东会，现将有 关事项通知如下： 一、召开会议基本情况 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：公司第六届董事会 3、会议召开的合法、合规性：本次召开股东会的议案经公司第六届董事会第二十 四次会议审议通过，符合有关法律法规、深圳证券交易所业务规则和《蓝帆医疗股份有 限公司章程》的规定。 4、会议召开的日期、时间： 6、股权登记日：2025 年 6 月 30 日（星期一）。 （1）现场会议时间：2025 年 7 月 7 日（星期一）下午 14：00 （2）网络投票时间：2025 年 7 月 7 日 通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时间 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 第六届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第二十四次会议于 2025 年 6 月 17 日以电子邮件的方式发出通知，于 2025 年 6 月 19 日以通讯表决的方式召 开。本次会议应参加会议董事 8 人，实际参加会议董事 8 人，全体董事以通讯的方式 出席会议。公司董事长刘文静女士主持了本次会议。会议的通知、召开、表决程序符合 《中华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议并通过了《关于董事会提议向下修正"蓝帆转债"转股价格的议案》； 本议案尚需提交股东会审议。 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 具体内容详见刊登于公司指定的信息披露媒体《中国证券报》、《上海证券 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 6 月 19 日，蓝帆医疗股份有限公司（以下简称"公司"）股价已 出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%的情形， 已触发"蓝帆转债"转股价格向下修正条件。 2、经公司第六届董事会第二十四次会议审议通过，公司董事会提议向下修正 "蓝帆转债"转股价格。 3、本次向下修正"蓝帆转债"转股价格的提议尚需提交公司股东会审议。 | 证券代码：002382 | 证券简称：蓝帆医疗 公告编号：2025-051 | | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | 蓝帆医疗股份有限公司 关于董事会提议向下修正"蓝帆转债"转股价格的公告 根据《蓝帆医疗股份有限公司公开发行可转换公司债券募集说明书》的规定，本 次发行的可转债转股期自可转债发行结束之日（2020 年 6 月 3 日）满六个月后的第一个 交易日（2020 年12 月 3 日）起至可转债到期日（2026 年 5 月27 日）止。 （四）可转债转股价格调整情况 1、公司于 ...

Group 1: Economic and Industrial Strength - Weifang is a manufacturing powerhouse, accounting for approximately 10% of the province's total manufacturing output and 1% of the national total [2] - The city has 37 out of 41 industrial categories in the national economy, including key sectors such as power equipment, high-end chemicals, and automotive manufacturing [2] - The industrial output value of large-scale enterprises has exceeded 1 trillion yuan for four consecutive years, with a projected growth of 8.5% in 2024, surpassing the provincial average by 0.2 percentage points [2] Group 2: Innovation and Technology - As of 2024, Weifang has 2,196 high-tech enterprises and 1,228 specialized and innovative companies, showcasing its strong innovation capabilities [3] - The city is actively developing emerging industries such as the metaverse and magnetic technology, promoting the transformation of manufacturing towards high-end, intelligent, and green development [3] Group 3: Agricultural Development - Weifang is recognized as a national agricultural hub, contributing significantly to the country's vegetable and agricultural product exports, with 16.8% of vegetables and 21.4% of agricultural product exports coming from the region [6][7] - The city has modernized its agricultural practices, with over 15,700 modern vegetable greenhouses and a significant portion of its vegetable base utilizing smart greenhouse technology [6] Group 4: International Cooperation and Trade - In 2024, Weifang organized the "Choose Shandong" multinational corporation event, facilitating discussions between 38 Fortune 500 companies and local enterprises, enhancing international cooperation [9] - The city achieved a total import and export value of 153.94 billion yuan in the first five months of 2025, reflecting a year-on-year growth of 5.1% [10] - Weifang has established investment relationships with 92 countries and regions, and its enterprises are involved in overseas projects in 72 countries [12]

证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-049 债券代码：128108 债券简称：蓝帆转债 的提示性公告 蓝帆医疗股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 关于预计触发可转债转股价格向下修正条件 特别提示： 1、证券代码：002382，证券简称：蓝帆医疗 2、债券代码：128108，债券简称：蓝帆转债 3、转股价格：人民币 12.50 元/股 4、转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 5、截至 2025 年 6 月 12 日，蓝帆医疗股份有限公司（以下简称"公司"）股票已 有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发"蓝帆转债"转股价格向 下修正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股 价格，并及时履行信息披露义务。 一、可转债发行上市基本情况 （一）可转债发行情况 （三）可转债转股期限 根据《蓝帆医疗股份有限公司公开发行可转换公司债券募集说明书》（以下简称 "《募集说明书》"）的规定，本次发行的可转债转股期自可转债发行结束之日（20 ...

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 心未来 近日， 蓝帆医疗 投资孵化的 外周介入板块 上海博脉安医疗科技有限公司 （简称" 博脉安医疗 "） 自主 研发的 金蚕™外周血管约束型球囊扩张导管 （国械注准20253030973）经过国家药品监督管理局审查 批准，正式获批上市。 金蚕™的获批标志着蓝帆医疗布局的外周介入业务线在复杂病变治疗领域再获重大突破。 产品特点 独特设计： 金蚕 ™外周血管约束型球囊扩张导管在半顺应性球囊表面设计了 镍钛记忆合金金属网 结构 ，具有独特 头端螺旋式金属网 设计，避免传统金属丝在回撤时刮擦血管壁，降低血栓风险， 同时保证球囊均匀回抱、安全回撤。 柔顺性增强： 间断镍钛丝网格设计 增强了球囊的柔顺性，确保球囊灵活翻山及通过迂曲病变部位。 随着中国居民生活水平提高以及对健康重视程度的不断提升，未来我国外周动脉介入手术量将不断增长。 近年来，我国外周动脉介入手术量不断增加，因此 国内外周动脉介入支架和球囊市场也将不断扩大 。 根据 ...

Core Viewpoint - The article highlights the recent advancements in peripheral vascular intervention technology, particularly focusing on the approval and features of the Jin Can™ peripheral vascular balloon dilation catheter developed by Bofei Medical, marking a significant breakthrough in the treatment of complex vascular diseases [1][17]. Product Features - The Jin Can™ catheter features a unique design with a nickel-titanium memory alloy metal mesh structure and a spiral metal mesh design at the tip, which reduces the risk of thrombosis and ensures safe retraction [3][17]. - Enhanced flexibility is achieved through an intermittent nickel-titanium wire mesh design, allowing the catheter to navigate through curved lesions effectively [3]. Market Overview - Peripheral artery disease, characterized by local stenosis or occlusion of peripheral arteries, is expected to see an increase in intervention procedures due to rising health awareness and living standards in China [5]. - The market for peripheral artery intervention balloons and stents in China is projected to grow to 6.8 billion yuan by 2030, driven by the increasing volume of procedures [5]. Market Growth Rates - The growth rates for balloon and stent markets from 2017 to 2030 are as follows: - Balloons: 30.5% (2017-2021), 21.5% (2021-2025E), 13.8% (2025E-2030E) - Stents: 14.7% (2017-2021), 11.0% (2021-2025E), 5.7% (2025E-2030E) - Overall market: 21.7% (2017-2021), 16.8% (2021-2025E), 11.0% (2025E-2030E) [7]. Competitive Landscape - The domestic PTCA balloon catheter market is characterized by significant competition, with major players including Demark, MicroPort, Lepu Medical, and Bofei Medical. However, foreign companies hold over 60% of the market share, with Boston Scientific and Medtronic accounting for nearly 50% [8][9]. - There remains substantial room for domestic manufacturers to increase their market share in the PTCA balloon catheter segment [9]. Recent Approvals - Bofei Medical's Jin Can™ balloon catheter was approved for market entry in June 2025, and the company has developed a comprehensive product matrix for peripheral vascular interventions [17]. - Other recent approvals include the SeaDragon™ ultra-high-pressure balloon catheter by Lanpai Medical and the peripheral balloon catheter by Youdebang Medical, both designed for various vascular applications [12][15]. Company Background - Bofei Medical, established in 2020, has developed a complete product line for peripheral vascular interventions, including the Jin Can™ catheter and other related products [17]. - Lanpai Medical, founded in 2002 and listed on the Shenzhen Stock Exchange, is a leading medical device company with a diverse portfolio covering various medical fields, including cardiovascular interventions [18].

| | | 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 蓝帆医疗股份有限公司（以下简称"公司"）根据《中华人民共和国公司法》、 《中 华人民共和国证券法》、《上市公司章程指引》及《上市公司自律监管指引第 1 号—— 主板上市公司规范运作》等法律法规的规定，并结合公司注册资本变更、治理结构调整 等实际情况，于 2025 年 4 月 25 日召开第六届董事会第二十一次会议、第六届监事会 第十四次会议，于 2025 年 5 月 20 日召开 2024 年年度股东大会，审议通过了《关于变 更注册资本、取消监事会暨修订 <公司章程> 的议案》，同意公司对注册资本进行变更， 公司注册资本由 1,007,105,539 元变更为 1,007,129,138 元；公司不再设置监事会，监事 会的职权由董事会审计委员会行使，并对《蓝帆医疗股份有限公司章程》相应条款予以 修订。上述内容详见公司分别于 2025 年 4 月 29 日、2025 年 5 月 21 日在《中国证券 报》、 《证券日报》和巨潮资讯网（ht ...